Source-grounded facts extracted from JUPITER NEUROSCIENCES, INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
JUPITER NEUROSCIENCES, INC. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2)).
“February 26, 2026, Jupiter Neurosciences, Inc. (the “ Company ”) received two written notices (each, a “ Notice ” and together, the “ Notices ”) from the Listing Qualifications Department of Nasdaq Stock Market LLC (“ Nasdaq ”) notifying the Company that (i) the listing of the Company’s common stock, par value $0.0001 per share (the “ Common Stock ”) was not in compliance with the minimum bid price requirement (the “ Minimum Bid Price Requirement ”) as set forth under Nasdaq Listing Rule 5550(a)(2) for continued listing of its Common Stock on The Nasdaq Capital Market, as the closing bid price”
Listing & Compliance Notices
JUPITER NEUROSCIENCES, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
“February 26, 2026, Jupiter Neurosciences, Inc. (the “ Company ”) received two written notices (each, a “ Notice ” and together, the “ Notices ”) from the Listing Qualifications Department of Nasdaq Stock Market LLC (“ Nasdaq ”) notifying the Company that (i) the listing of the Company’s common stock, par value $0.0001 per share (the “ Common Stock ”) was not in compliance with the minimum bid price requirement (the “ Minimum Bid Price Requirement ”) as set forth under Nasdaq Listing Rule 5550(a)(2) for continued listing of its Common Stock on The Nasdaq Capital Market, as the closing bid price”
Material Agreements
JUPITER NEUROSCIENCES, INC. amended Omnibus Amendment with YA II PN, LTD (effective 2026-02-20).
“On February 20, 2026, the Company and Yorkville entered into an Omnibus Amendment (the “Amendment”) to revise Section 1(c) of the A&R Convertible Notes, the “Monthly Payments” provision.”
Debt Financings
JUPITER NEUROSCIENCES, INC. incurred convertible notes of $4.0 million with YA II PN, LTD.
“The first Pre-Paid Advance in the amount of $3,720,000 was disbursed to the Company on October 27, 2025, in exchange for the Company’s issuance to Yorkville of a Convertible Note in the principal amount of $4.0 million, which was issued with an “original issue discount” (“OID”) of 7.0% (or $280,000) and is initially convertible into Common Stock at a fixed conversion price of $1.50 per share (subject to adjustment as provided in such Convertible Note) (the “First Convertible Note”).”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.